ASCELIA – AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

OUR STORY

Our Vision

Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.

Learn more about us:

Ascelia Pharma company presentation May 2022

Q1-2022 investor conference call

Quarterly Report Q1-2022

About us

TOP STORIES

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

2022.04.11

TOP STORIES

Oncoral featured in the journal International Pharmaceutical Industry

2022.04.08

In the April edition of the International Pharmaceutical Industry Journal, you can read about the science and our work to improve the outcomes for gastric cancer patients through our innovative daily oral chemotherapy drug candidate, Oncoral.

“Improving outcomes for gastric cancer patients via a novel dose chemotherapy formulation, Oncoral”.

TOP STORIES

New market research shows strong support for Orviglance

2022.03.29

TOP STORIES

Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

2022.03.11

Ascelia Pharma today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead drug candidate Orviglance®.

TOP STORIES

Orviglance featured in the journal International Clinical Trials

2022.03.03

In the February 2022 edition of the journal International Clinical Trials, you can read about our novel contrast agent Orviglance.

“A New Approach to Imaging Focal Liver Lesions in Patients With Reduced Kidney Function.”

Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q1 2022 (January – March 2022), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/

2022-05-10

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

Ascelia Pharma AB (publ) (ticker: ACE) today announced the results of the Food Effect Study that evaluated the effect of food intake on absorption and signal intensity of Orviglance®. The results showed that intake of a light meal prior to Orviglance administration provides similar image MRI enhancement of the liver compared to a fasting condition. …

2022-05-05

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022

Today, on 5 May 2022, the annual general meeting was held in Ascelia Pharma AB. The annual gen-eral meeting was held only by advance voting (postal vote) in accordance with temporary legisla-tion. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.

View all

Presentations & Articles

2022-04-27

Redeye Orphan Drug Day

Chief Medical Officer, Carl Bjartmar presents at Redeye Orphan Drug Day

2022-04-08

Oncoral featured in the journal International Pharmaceutical Industry

2022-03-29

New Market Research Shows Strong Support for Orviglance

New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The research confirms the clear unmet need for an effective alternative to unenhanced MRI and a safe alternative to gadolinium contrast agents.

View all

INVESTOR

Shortcut to our latest Financial Reports

IR & Media

Warning: Undefined variable $video_width in /var/www/ascelia.com/public_html/wp-content/themes/ascelia/template-parts/block/content-big-link-with-image.php on line 35

Warning: Undefined variable $video_height in /var/www/ascelia.com/public_html/wp-content/themes/ascelia/template-parts/block/content-big-link-with-image.php on line 35

PEOPLE

Meet our CEO Magnus Corfitzen

Listen to Ascelia Pharma’s CEO Magnus Corfitzen and the vision and plans for the company

ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

ADVANCING
ORPHAN ONCOLOGY

Our Vision

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

Oncoral featured in the journal International Pharmaceutical Industry

New market research shows strong support for Orviglance

Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

Orviglance featured in the journal International Clinical Trials

Upcoming Events

Ascelia Pharma to present at ESGAR Conference

Half-year report 2022

Interim report 9M

Latest News

Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022

Presentations & Articles

Redeye Orphan Drug Day

Oncoral featured in the journal International Pharmaceutical Industry

New Market Research Shows Strong Support for Orviglance

Shortcut to our latest Financial Reports

Meet our CEO Magnus Corfitzen

About us

Meet us

Our values

About us

Pipeline

IR & Media

Contact us

Follow us

ADVANCINGORPHAN ONCOLOGY

Our Vision

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

Oncoral featured in the journal International Pharmaceutical Industry

New market research shows strong support for Orviglance

Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

Orviglance featured in the journal International Clinical Trials

Upcoming Events

Ascelia Pharma to present at ESGAR Conference

Half-year report 2022

Interim report 9M

Latest News

Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022

Presentations & Articles

Redeye Orphan Drug Day

Oncoral featured in the journal International Pharmaceutical Industry

New Market Research Shows Strong Support for Orviglance

Shortcut to our latest Financial Reports

Meet our CEO Magnus Corfitzen

About us

Meet us

Our values

ADVANCING
ORPHAN ONCOLOGY